MX2020003806A - Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. - Google Patents
Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.Info
- Publication number
- MX2020003806A MX2020003806A MX2020003806A MX2020003806A MX2020003806A MX 2020003806 A MX2020003806 A MX 2020003806A MX 2020003806 A MX2020003806 A MX 2020003806A MX 2020003806 A MX2020003806 A MX 2020003806A MX 2020003806 A MX2020003806 A MX 2020003806A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- prevention
- treatment
- monoclonal antibodies
- antibodies targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente se describe una composición que incluye una secuencia de ácidos nucleicos recombinantes que codifica un anticuerpo o fragmento de este que se dirige a CTLA-4; la descripción también proporciona un método para prevenir y/o tratar una enfermedad, tal como el cáncer, en un sujeto usando la composición de la invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762569470P | 2017-10-06 | 2017-10-06 | |
PCT/US2018/054137 WO2019070834A1 (en) | 2017-10-06 | 2018-10-03 | MONOCLONAL DNA ANTIBODIES TARGETING CTLA-4 FOR THE TREATMENT AND PREVENTION OF CANCER |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003806A true MX2020003806A (es) | 2020-11-09 |
Family
ID=65995298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003806A MX2020003806A (es) | 2017-10-06 | 2018-10-03 | Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200283525A1 (es) |
EP (1) | EP3691694A4 (es) |
JP (1) | JP2020536114A (es) |
KR (1) | KR20200060759A (es) |
CN (1) | CN111971071A (es) |
AU (1) | AU2018345715A1 (es) |
BR (1) | BR112020006879A2 (es) |
CA (1) | CA3078458A1 (es) |
MX (1) | MX2020003806A (es) |
RU (1) | RU2020115161A (es) |
WO (1) | WO2019070834A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2963226T3 (es) | 2016-12-07 | 2024-03-26 | Agenus Inc | Anticuerpos ANTI-CTLA-4 y métodos de uso de los mismos |
WO2023064841A1 (en) * | 2021-10-13 | 2023-04-20 | The Wistar Institute Of Anatomy And Biology | Antibodies for use against sars-cov-2 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7919079B2 (en) * | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
BRPI0812913B8 (pt) * | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
KR102017898B1 (ko) * | 2010-05-14 | 2019-09-04 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
BR112013006699A2 (pt) * | 2010-09-24 | 2016-06-14 | Oncos Therapeutics Oy | vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral |
US20160355573A1 (en) * | 2013-09-05 | 2016-12-08 | Cornell University | Gene therapy for alzheimer's and other neurodegenerative diseases and conditions |
CN105658799A (zh) * | 2013-10-07 | 2016-06-08 | 普雷斯蒂奇生物制药私人有限公司 | 用于抗体表达的双顺反子表达载体以及用其生产抗体的方法 |
CN105829341A (zh) * | 2013-12-13 | 2016-08-03 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
ES2727137T3 (es) * | 2014-08-28 | 2019-10-14 | Halozyme Inc | Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario |
KR20170085131A (ko) * | 2014-12-01 | 2017-07-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Dna 항체 작제물 및 그 이용 방법 |
EP3400023A1 (en) * | 2016-01-10 | 2018-11-14 | ModernaTX, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
US11896654B2 (en) * | 2016-05-05 | 2024-02-13 | The Trustees Of The University Of Pennsylvania | DNA monoclonal antibodies targeting checkpoint molecules |
-
2018
- 2018-10-03 EP EP18864252.4A patent/EP3691694A4/en active Pending
- 2018-10-03 AU AU2018345715A patent/AU2018345715A1/en active Pending
- 2018-10-03 BR BR112020006879-9A patent/BR112020006879A2/pt unknown
- 2018-10-03 US US16/753,870 patent/US20200283525A1/en active Pending
- 2018-10-03 CA CA3078458A patent/CA3078458A1/en active Pending
- 2018-10-03 WO PCT/US2018/054137 patent/WO2019070834A1/en unknown
- 2018-10-03 KR KR1020207012559A patent/KR20200060759A/ko not_active Application Discontinuation
- 2018-10-03 JP JP2020519796A patent/JP2020536114A/ja active Pending
- 2018-10-03 MX MX2020003806A patent/MX2020003806A/es unknown
- 2018-10-03 CN CN201880077635.8A patent/CN111971071A/zh active Pending
- 2018-10-03 RU RU2020115161A patent/RU2020115161A/ru unknown
Also Published As
Publication number | Publication date |
---|---|
KR20200060759A (ko) | 2020-06-01 |
EP3691694A4 (en) | 2021-07-07 |
JP2020536114A (ja) | 2020-12-10 |
CA3078458A1 (en) | 2019-04-11 |
RU2020115161A (ru) | 2021-11-08 |
AU2018345715A8 (en) | 2020-05-28 |
US20200283525A1 (en) | 2020-09-10 |
EP3691694A1 (en) | 2020-08-12 |
RU2020115161A3 (es) | 2022-01-28 |
AU2018345715A1 (en) | 2020-05-21 |
BR112020006879A2 (pt) | 2020-10-06 |
CN111971071A (zh) | 2020-11-20 |
WO2019070834A1 (en) | 2019-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550214A1 (en) | Antibodies specific to cd47 and pd-l1 | |
MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
MX2024000125A (es) | Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control. | |
NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
MX2017014955A (es) | Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
EA201890175A1 (ru) | Антитела к cd40 | |
PE20190737A1 (es) | Anticuerpos anti-cd27 | |
MD20170031A2 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
UA117364C2 (uk) | Похідні аматоксину | |
PH12019502298A1 (en) | Monoclonal antibody to pd-l1 | |
CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
MX2020003806A (es) | Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. | |
BR112017025036A2 (pt) | peptídeo; ácido nucleico; parcela de ligação; composição farmacêutica; peptídeos e/ou ácidos nucleicos e/ou parcelas de ligação; peptídeos e/ou ácidos nucleicos e/ou parcelas de ligação para uso; e ácido nucleico para uso | |
MX2024006292A (es) | Anticuerpos monoclonales de adn dirigidos al virus de la influenza. | |
BR112017013420A2 (pt) | anticorpo adam17 humanizado | |
BR112022002761A2 (pt) | Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40 | |
PH12020550218A1 (en) | MONOCLONAL ANTIBODY TO IL-5Ra | |
MX2020013923A (es) | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. | |
EA202092121A1 (ru) | Антитела против cd73 и их применения | |
EA202092981A1 (ru) | Антитела к l1cam и их применение |